ipilimumab

• 

Triple combination for previously untreated advanced non-clear cell kidney cancer

By Sharon Deveson Kell|2023-06-08T08:24:50+00:007 Jun 2023|Drug treatments|

The COSMIC-313 study previously showed improved survival when combining cabozantinib [...]

Read More

Comments Off on Triple combination for previously untreated advanced non-clear cell kidney cancer

• 

Triple combination improves survival in patients with advanced kidney cancer

By Sharon Deveson Kell|2023-05-15T08:11:29+00:0015 May 2023|Drug treatments|

Results from the phase 3 COSMIC-313 trial showed that adding [...]

Read More

Comments Off on Triple combination improves survival in patients with advanced kidney cancer

• 

Brain metastases from kidney cancer treated with first-line therapies

By Sharon Deveson Kell|2023-04-14T10:25:34+00:0014 Apr 2023|Drug treatments, Surgery|

A recent study looked at the outcomes of patients with [...]

Read More

Comments Off on Brain metastases from kidney cancer treated with first-line therapies

• 

Adjuvant nivolumab plus ipilimumab for localised kidney cancer

By Sharon Deveson Kell|2023-03-20T09:50:05+00:0020 Mar 2023|Drug treatments|

In this randomised phase 3 trial, the effectiveness and safety [...]

Read More

Comments Off on Adjuvant nivolumab plus ipilimumab for localised kidney cancer

• 

How time of day of immunotherapy infusion affects kidney cancer outcomes

By Sharon Deveson Kell|2023-03-16T08:32:10+00:0016 Mar 2023|Drug treatments|

Recent studies have suggested that the time of day when [...]

Read More

Comments Off on How time of day of immunotherapy infusion affects kidney cancer outcomes

• 

ASCO GU 2023: A triple combination for previously untreated kidney cancer patients

By Sharon Deveson Kell|2023-03-07T14:33:29+00:007 Mar 2023|Drug treatments|

At the American Society of  Clinical Oncology Genitourinary Cancers Conference [...]

Read More

Comments Off on ASCO GU 2023: A triple combination for previously untreated kidney cancer patients

• 

ASCO GU 2023: Treatment-free survival for advanced kidney cancer patients on nivolumab and salvage nivolumab/ipilimumab

By Sharon Deveson Kell|2023-03-06T14:59:34+00:006 Mar 2023|Drug treatments|

In this study presented at the American Society of Clinical [...]

Read More

Comments Off on ASCO GU 2023: Treatment-free survival for advanced kidney cancer patients on nivolumab and salvage nivolumab/ipilimumab

• 

Adjuvant nivolumab plus ipilimumab in localised kidney cancer

By Sharon Deveson Kell|2023-02-27T10:20:33+00:0027 Feb 2023|Drug treatments|

A recent phase 3 study called CheckMate 914 has shown [...]

Read More

Comments Off on Adjuvant nivolumab plus ipilimumab in localised kidney cancer

• 

Nivolumab plus ipilimumab for advanced kidney cancer after progression on immunotherapy

By Sharon Deveson Kell|2022-11-15T09:09:15+00:0015 Nov 2022|Drug treatments|

This phase 2 study looked at the effect on survival [...]

Read More

Comments Off on Nivolumab plus ipilimumab for advanced kidney cancer after progression on immunotherapy

• 

Ipilimumab-nivolumab and axitinib-pembrolizumab combinations produce similar survival times

By Sharon Deveson Kell|2022-10-27T08:20:36+00:0027 Oct 2022|Drug treatments|

When ipilimumab plus nivolumab or axitinib plus pembrolizumab are used [...]

Read More

Comments Off on Ipilimumab-nivolumab and axitinib-pembrolizumab combinations produce similar survival times